1. A composition for treating and/or preventing disorders which promotes hemostasis comprising at least one procoagulation agent and at least one inhibiting agent which inhibits a costimulatory molecule on the surface of antigen-presenting cells and a corresponding receptor in a T cell such that the immune response is downmodulated to thereby treat a hemostatic disorder. 2. The composition of claim 1, further comprising a pharmaceutically acceptable carrier. 3. The composition of claim 1, wherein the procoagulation agent is factor VIII. 4. The composition of claim 1, wherein the procoagulation agent is a B-domain deleted variant of factor VIII. 5. The composition of claim 1, wherein the procoagulation agent is factor IX. 6. The composition of claim 1, wherein the procoagulation agent is Von Willebrand factor. 7. The composition of claim 1, wherein the inhibiting agent is a soluble form of a costimulatory molecule. 8. The composition of claim 7, wherein the inhibiting agent is a soluble form of CTLA4. 9. The composition of claim 7, wherein the inhibiting agent is a soluble form of B7-1, a soluble form of B7-2, or a combination thereof. 10. The composition of claim 8, wherein the inhibiting agent is CTLA4Ig. 11. The composition of claim 9, wherein the inhibiting agent is B7-lIg or B72Ig. 12. The composition of claim 1, wherein the inhibiting agent is an antibody which binds to a costimulatory molecule. 13. The composition of claim 12, wherein said antibody is selected from the group consisting of an anti-B7-1 antibody, anti-B7-2 antibody, and a combination thereof. 14. The composition of claim 12, wherein the antibody does not transduce a costimulatory signal in a T cell. 15. A method of treating a hemostatic disorder in a subject comprising administering to the subject a therapeutically effective composition of any one of claims 1-14. 16. The method of claim 15, wherein the subject has a preexisting immune response to the procoagulation agent. 17. The method of claim 15, wherein the subject does not have a preexisting immune response to the procoagulation agent. 18. The method of claim 15, further comprising administering the subject a composition comprising an additional immunosuppressive agent. 19. The composition of claim 15, wherein the subject has a hemostatic disorder of hemophilia A, hemophilia B, and von Willebrand's disease. 20. A method for treating disorders promoting hemostasis comprising administering a therepeutically effective composition to the subject at least one procoagulation agent and at least inhibiting agent which inhibits a costimulatory molecule on the surface of antigen-presenting cells and a corresponding receptor in a T cell such that the immune response is downmodulated to thereby treat a hemostatic disorder. 21. The method of claim 20, wherein the procoagulation agent is factor VIII. 22. The method of claim 20, wherein the procoagulation agent is a B-domain deleted variant of factor VIII. 23. The method of claim 20, wherein the procoagulation agent is factor IX. 24. The method of claim 20, wherein the procoagulation agent is Von Willebrand factor. 25. The method of claim 20, wherein the inhibiting agent is a soluble form of a costimulatory molecule. 26. The method of claim 25, wherein the inhibiting agent is a soluble form of CTLA4. 27. The method of claim 26, wherein the inhibiting agent is a soluble form of CTLA4Ig. 28. The method of claim 25, wherein the inhibiting agent is a soluble form of B7-1, a soluble form of B7-2, or a combination thereof. 29. The method of claim 28, wherein the inhibiting agent is B7-1Ig, B7-2Ig or a combination thereof. 30. The method of claim 20, wherein the inhibiting agent is an antibody which binds to a costimulatory molecule. 31. The method of claim 30, wherein said antibody is selected from the group consisting of an anti-B7-1 antibody, an anti-B7-2 antibody and a combination thereof. 32. The method of claim 30, wherein the antibody does not transduce a costimulatory signal in a T cell. 33. The method of claim 20, wherein the subject has a hemostatic disorder of hemophilia A, hemophilia B, and von Willebrand's disease. 34. The method of claim 20, wherein the subject has a significant titer of antibodies which bind to the procoagulation agent.